🩺 Patient Case Phenotyper & Clinical Triage

⚡ REAL-TIME CLINICAL ENGINE ACTIVE

What is KDIGO?
KDIGO stands for Kidney Disease: Improving Global Outcomes. It is the worldwide gold standard for diagnosing and staging diabetic kidney disease using eGFR (G1–G5) and Albuminuria (A1–A3).

Renal Dosing Audits:
KDIGO 2022 mandates capping Metformin at 1,000 mg/day at eGFR 30–44 mL/min (G3b) and stopping Metformin completely at eGFR < 30 mL/min (G4/G5) to prevent fatal lactic acidosis.

Individualized Targets:
ADA 2024 and RSSDI personalize HbA1c goals based on patient age, CKD stage, and severe hypoglycemia risk (<6.5% for young/healthy vs <8.0% for frail elderly).

Severe Hyperglycemia (HbA1c > 10%):
When HbA1c is ≥ 10.0%, guidelines recommend immediate dual combination therapy or injectable basal insulin/GLP-1 RA intensification.

📋 1-Click Clinical Case Presets:

Case 1: 64y CKD Stage 3b (eGFR 38) + Metformin Cap Case 2: 58y Established ASCVD (Post-MI) + Pharmacotherapy Case 3: 70y Heart Failure + Pioglitazone Alert Case 4: 79y Frail Elderly + Hypoglycemia Avoidance Case 5: 68y CKD Stage 4 (eGFR 24) + Metformin Stop

Patient Clinical Labs:

ACTIVE CLINICAL EVALUATION: Age 64y · HbA1c 10.2% · eGFR 38 mL/min · UACR 150 mg/g

Patient HbA1c ≥ 10.0% (or ≥ 2.0% above individualized target). Monotherapy is insufficient. Prompt initiation of Dual Combination Therapy or Injectable Therapy (Basal Insulin + GLP-1 RA) is recommended to achieve rapid glycemic rescue and prevent glucose toxicity.